# Nuclide record ac225-psma (drug). Data CC BY-NC 4.0, attribute "Data from Nuclide (nuclide.cc)". Whole corpus: https://nuclide.cc/api/v1/nuclide.nt
@prefix schema: <https://schema.org/> .
@prefix nuclide: <https://nuclide.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://nuclide.cc/drugs/ac225-psma/>
  a schema:Drug ;
  nuclide:kind "drug" ;
  schema:identifier "ac225-psma" ;
  schema:name "Actinium-225 PSMA agents"@en ;
  schema:description "Alpha-emitting PSMA drugs that produce responses even after Pluvicto fails, held back mainly by isotope supply."@en ;
  schema:url <https://nuclide.cc/drugs/ac225-psma/> ;
  schema:dateModified "2026-09-04"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/search?intr=225Ac-PSMA-617> ;
  nuclide:status "phase-3" ;
  nuclide:modality "Targeted alpha therapy" ;
  nuclide:related <https://nuclide.cc/isotopes/ac-225/> ;
  nuclide:indications <https://nuclide.cc/indications/prostate/>, <https://nuclide.cc/indications/prostate-mcrpc/> ;
  nuclide:technologies <https://nuclide.cc/technologies/targeted-alpha-therapy/> ;
  nuclide:targets <https://nuclide.cc/targets/psma/> ;
  nuclide:companies <https://nuclide.cc/companies/novartis/>, <https://nuclide.cc/companies/bayer/>, <https://nuclide.cc/companies/fusion-pharma/>, <https://nuclide.cc/companies/astrazeneca/> ;
  nuclide:trials <https://nuclide.cc/trials/nct07590934/> .